IL6 and colorectal carcinoma: Furthermore, numerous studies have demonstrated the unusually high activation of the IL-6/JAK2/STAT3 signaling pathway in a range of malignancies, including gastric, breast, liver, colorectal (CRC), colon, ovarian (OC), lung, and pancreatic cancers [28].